Pegylated Interferon/Ribavirin dual therapy in patients with chronic Hepatitis C: results of 323 cases

Authors : Aynur Atilla, Emel Duyar, Fatih Bostancı, S Sırrı Kılıç

Pages : 151-155

Doi:10.5799/ahinjs.02.2015.04.0196

View : 12 | Download : 6

Publication Date : 2016-02-06

Article Type : Other Papers

Abstract :Objective: The combination of pegylated interferon-α insert ignore into journalissuearticles values(PEG-IFN); and ribavirin has become a mainstay in the treatment of chronic hepatitis C insert ignore into journalissuearticles values(CHC);. We aimed to evaluate the efficacy of this treatment in patients with CHC, while considering new approaches. Methods: A total of 323 patients with CHC underwent PEG-IFN and ribavirin combination treatment from the 3 centers insert ignore into journalissuearticles values(2 in Ordu and 1 in Samsun provinces); in Middle Black Sea region between the years of 2003-2013. Results: Of the patients, 208 insert ignore into journalissuearticles values(67%); were female and had a mean age 54 ± 10 years insert ignore into journalissuearticles values(median: 54; 19-70);. Genotyping was performed in 163 patients, and 161 patients insert ignore into journalissuearticles values(98.8%); revealed genotype 1. Sustained virologic response insert ignore into journalissuearticles values(SVR); and the end of treatment response rates ere 58.3% and 75.6%, respectively. In patients with rapid virological response, the SVR rate was 85.1%, whereas in patients with a HCV RNA level less than 800,000 IU/ml, the SVR rate was 71.2%. The SVR rates were found to be higher in patients who developed hypothyroidism, which was statistically significant insert ignore into journalissuearticles values(p = 0.03);. The most frequent side effect was anemia, followed by thrombocytopenia, fatigue, and loss of appetite. Conclusion: Presently, PEG-IFN/ribavirin is still an option in the treatment of certain patient populations even after the consideration of newer treatment methods. J Microbiol Infect Dis 2015;5insert ignore into journalissuearticles values(4);: 151-155 Key words: Pegylated interferon, ribavirin, therapy, hepatitis C
Keywords :